'Beyond our expectations': How to invest in obesity drugs like Ozempic with ASX ETFs

This could be your way to invest in obesity drugs.

medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price has come under significant pressure in recent months due to the emergence of obesity drugs.

With analysts forecasting huge growth in demand for drugs like Ozempic over the next decade, there are concerns that ResMed could lose some of its sleep apnoea customer base. That's because research shows that 70% of obstructive sleep apnoea (OSA) patients are obese.

The good news is that most analysts believe this is an overreaction and that there's still a huge market for ResMed to grow into outside any Ozempic impacts.

But what about Ozempic and other obesity drugs? Should we be investing in them as well?

The team at Morgan Stanley believes it could be a good idea based on its expectations for explosive growth through to 2030.

Morgan Stanley's European Biopharmaceuticals analyst, Mark Purcell, commented:

Social media activity documenting transformative weight loss, together with the establishment of affordable insurance coverage more quickly than anticipated, has helped drive demand for obesity medicines beyond our expectations. While supply constraints have capped sales growth in the near term, the global obesity market could go from a $2.4 billion category in 2022 to reach $77 billion in 2030, up from our previous estimate for a $54 billion.

ASX ETFs to the rescue

The simplest way to invest in Ozempic and other obesity drugs is to go directly to the source.

In the case of Ozempic, this would mean investing in Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), which is listed on Wall Street.

As for Mounjaro, a diabetes treatment being repurposed as an obesity drug, it is owned by US pharmaceutical behemoth Eli Lilly And Co (NYSE: LLY).

However, if you're not keen on going down this route, then you could look at ASX ETFs.

The VanEck Global Healthcare Leaders ETF (ASX: HLTH) gives investors access to 50 of the largest international companies from the global healthcare sector. Its holdings include both Eli Lilly & Co and Novo Nordisk.

Alternatively, the BetaShares Global Healthcare ETF – Currency Hedged (ASX: DRUG) could be another way to do it. It is invested in a touch under 70 global healthcare shares, with Eli Lilly & Co and Novo Nordisk making up a total weighting of 12.9% of the portfolio.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Novo Nordisk. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ETFs

ETF written on coloured cubes which are sitting on piles of coins.
ETFs

Is the Vanguard MSCI Index International Shares ETF (VGS) unit price a buy for passive income?

Can the VGS ETF provide the distributions investors are looking for?

Read more »

couple happily discussing their issues with a banker
ETFs

3 ASX ETFs that could be strong buys next month

Let's see why these funds could be top picks for investors looking to make some portfolio additions in August.

Read more »

Soldier in military uniform using laptop for drone controlling.
ETFs

Here is what you're invested in with ARMR ETF

The ARMR ETF provides a way of investing in the emerging global defence theme.

Read more »

Exchange-traded fund spelt out with ETF in red and a person pointing their finger at it.
ETFs

2 of the best ASX ETFs to buy and hold for a decade or more

Let's see what makes these funds stand out from the rest.

Read more »

a group of people in business attire gather around a computer in an office environment with expressions of concern as they try to nut out the answer to a challenge they are facing.
ETFs

What are the 2 biggest ASX ETF themes today?

Betashares reveals the two best-performing segments of the ASX ETF market in the second half of FY25.

Read more »

a couple and their baby sit together at their computer carrying out digital transactions and smiling happily.
ETFs

5 reasons why the Vanguard Australian Shares Index ETF (VAS) is a great investment for most Australians

There are a number of positives to like about this fund…

Read more »

ETF spelt out with a rising green arrow.
ETFs

5 high-quality ASX ETFs to buy in August

Let's see what makes these funds top picks for Aussie investors.

Read more »

A businesswoman weighs up the stack of cash she receives, with the pile in one hand significantly more than the other hand.
ETFs

Does the VanEck Wide Moat ETF really have a 6% dividend yield right now?

How can an American-focused ETF pay such a big yield?

Read more »